Can-Fite BioPharma (NYSE:CANF) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note published on Thursday. The brokerage issued a sell rating on the stock.

Several other brokerages also recently commented on CANF. D. Boral Capital restated a “buy” rating and issued a $10.00 target price on shares of Can-Fite BioPharma in a research note on Tuesday, December 31st. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Can-Fite BioPharma Stock Performance

Shares of CANF opened at $1.81 on Thursday. The firm has a market cap of $6.41 million, a P/E ratio of -1.01 and a beta of 1.32. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69. The business has a 50-day moving average of $1.85 and a 200 day moving average of $2.35.

Institutional Investors Weigh In On Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC grew its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the period. Armistice Capital LLC owned approximately 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. Institutional investors own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.